A team of researchers at the Regional Centre for Biotechnology (RCB), Faridabad created a mouse model with a deleted MYH3 gene to study congenital musculoskeletal disorders. They found that the loss of this gene led to traits resembling spondylocarpotarsal synostosis syndrome (SCTS) in adult mice, shedding light on MYH3-associated conditions. This work holds promise for understanding rare genetic disorders.
A research group working on packaging antitumour drugs from Regional Centre for Biotechnology, Faridabad, and Amity University, Haryana, has successfully trained immune cells to attack tumour cells. They have developed a hydrogel-based anticancer drug delivery system that reduces toxicity and targets tumours directly. This innovation shows promise for more effective cancer treatment pending further research and clinical trials.
Researchers from the Indian Institute of Science, Bangalore, have demonstrated Picolinic acid's (PA) potential against pandemic viruses, specifically SARS-CoV-2 and Influenza A, through broad-spectrum antiviral activity and immune response enhancement. The study emphasises PA's promising therapeutic role and its unique mechanism targeting viral entry and immune modulation.
In a collaborative study, researchers from the SN Bose National Centre for Basic Sciences, Kolkata, Uluberia College, University of Calcutta, and other institutes made an exciting discovery in treating ulcerative colitis, a prevalent chronic inflammatory bowel disease (IBD). By using chitosan-capped trimanganese tetraoxide nanoparticles, they effectively treated the disease in mice, offering the potential for future therapeutic advancements in this debilitating condition.
A team of researchers at the Indian Institute of Technology (IIT), Kanpur, have identified a key determinant motif in the G protein-coupled receptors (GPCRs) that facilitates its interaction with β-arrestins. The study provides crucial insights into the complex mechanism, opening new avenues for therapeutic interventions and advancing our understanding of GPCR-mediated signalling.
A recent study led by Partha Chakrabarti, CSIR-Indian Institute of Chemical Biology, Kolkata, explores the therapeutic potential of gut microbiota in preventing non-alcoholic fatty liver disease (NAFLD). The study found that butyrate, a metabolite produced by gut bacteria, effectively reduces inflammation in liver macrophages, suggesting a potential treatment approach for NAFLD.
A team of researchers from the Indian Institute of Science, Bengaluru has explored a new approach to treat mycobacterial infections, which are becoming increasingly drug-resistant. They found that a cocktail of mycobacteriophages – viruses that infect mycobacteria but not humans– were effective against slow- and fast-growing mycobacteria, in cultures. This has clinical significance in treating tuberculosis (caused by M.tuberculosis, a slow-growing mycobacterium), which is of concern, especially in developing countries. In this article, Edna George reports on this recent study by Rachit Agarwal’s team.